Breast cancer (BC) is the leading cancer in women worldwide. Changes in DNA methylation in peripheral blood could be associated with malignant diseases. Making use of screening results by llumina 27K Methylation Assay, we validated demethylation of five CpG sites of S100P gene in blood cell DNA of BC patients by three independent retrospective studies with subjects from different centers (Validation I: 235 familial BC case and 206 controls, odds ratio per −1% methylation > 1.03, and P < 6.00 × 10 -8 for all five CpG sites; Validation II: 189 sporadic BC case and 189 controls, odds ratio per −1% methylation > 1.03, P < 8.0 × 10 -5 for four CpG sites; Validation III: 156 sporadic BC case and 151 controls, odds ratio per −1% methylation > 1.03, P < 6.0 × 10 -4 for four CpG sites). In addition, the blood-based S100P methylation pattern was similar among BC patients with differential clinical characteristics regardless of stage, receptor status and menopause status. The observed BC-associated decreased S100P methylation in blood mainly originates from the leucocytes subpopulations but not B cells. The methylation levels of most S100P CpG sites were inversely correlated with the expression of S100P in leucocytes (P < 1.2 × 10 -4 ) and in tissue (P < 1. 1 × 10 -4 ). This study reveals significant association between blood-based decreased S100P methylation and BC, and provides another proof for the application of altered DNA methylation signatures from blood cells as potential markers for the detection of BC, especially for the early stage. R.Yang et al. | 313 
Introduction
As the most frequent cancer and the leading cause of cancerrelated mortality among women, breast cancer (BC) had 1.7 million new cases and 522 000 deaths in 2012 (1) . In United States and Europe, one woman in eight will develop BC in her lifetime (2) . Since the outcome for women with non-metastatic BC is closely correlated with the number of axiliary node involved and with tumor size, the early detection for BC is necessary and appreciated (3, 4) . Understanding of BC-related markers and making use of liquid biopsy, may improve the chance to detect early BC.
Epigenetics is defined as changes in gene expression that are not due to any alterations in the DNA sequence. Epigenetic silencing can mimic genetic mutation by impairing expression of a gene (5) . Therefore, aberrant epigenetic signatures have been considered as disease related (5) . DNA methylation is one of the most important epigenetic signatures, and has critical roles in the control of gene activities and the architecture of the nucleus of the cell (6, 7) . Hypermethylation in tumor suppressor genes and hypomethylation in oncogenes are important characters of cancer (8, 9) .
As an early event in the development of cancer, aberrant DNA methylation signatures are particularly promising markers for the detection of early BC (5, 8, 10) . Intensive studies have disclosed altered DNA methylation signatures in circulating free DNA (cfDNA) of BC patients (11) (12) (13) (14) (15) , whereas only a few studies have analysed methylation signatures in DNA from blood cells (16) (17) (18) (19) . Recently, two large genome-wide studies have reported BC-associated epigenome-wide hypomethylation in the peripheral blood DNA (20, 21) . In our previous study, aberrant DNA methylation in blood cells was studied by epigenomewide investigation using Infinium 27K Methylation Array, and validated BC-associated HYAL2 hypomethylation in independent studies by MassARRAY (22) . With a similar methodology, we hereby conducted a validation for further BC-associated differentially DNA methylation in peripheral blood by case-control studies in the Caucasian population.
Materials and methods

Discovery cohort and the Infinium 27K methylation assay
The 96 samples for the discovery round were described in our previous study (22) . Genomic DNA from each sample was bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo Research) and subsequently subjected to the genome-wide methylation screening using the Human Methylation27 BeadChip (Illumina) according to the manufacturer's recommendations. All the 96 samples passed the quality control.
Study population of the three independent validation cohorts
The present study was approved by the Ethics Committee of the University of Heidelberg (Germany). The BC patients and the healthy controls of the three cohorts have been matched by median of age, ethic group (Caucasian) and geographic region (Southwest Germany). No further criteria were applied for the selection of samples. For more details of the studies, please see Table 1 . All the recruited subjects gave written informed consent. The clinical characteristics of BC patients were defined according to the American Joint Committee on cancer staging manual (23) . Genomic DNA was isolated from peripheral whole blood using DNA isolation kits from Qiagen (Hilden, Germany).
Validation I
The validation I was described in our previous study (22) . In brief, peripheral whole blood samples from 206 BRCA1/2 mutation-negative index familial BC (FBC) patients were collected retrospectively by the centers of the German Consortium for Hereditary Breast and Ovarian Cancer during the years 1997-2007 (43.0 ± 8.6 years old). Peripheral whole blood samples were consecutively collected from blood donors by the German Red Cross Blood Service of Baden-Württemberg-Hessen (Mannheim, Germany). None of the control individuals had a reported family history of BC (24) . 235 unrelated and cancer free females were randomly selected during the years 2004-2010 from the blood bank as controls for validation I (43.0 ± 9.4 years old). No further inclusion criteria were applied during recruitment of controls.
Validation II
The validation II was described in our previous study (22) . Peripheral whole blood samples from 189 sporadic BC (SBC) patients were collected retrospectively at the time point of first BC diagnosis before any BC treatment and surgery at the University Hospital of Heidelberg in the year of 2009 and 2010 (60 ± 11.7 years old). 189 unrelated and cancer free females collected during the years 2004-2010 from the blood bank of German Red Cross Blood Service of Baden-Württemberg-Hessen were randomly selected as controls (63 ± 9.4 years old). Although obtained from the same center, the controls for Validation II were independent from Validation I. No further inclusion criteria were applied during recruitment of controls.
Validation III
Peripheral blood samples from 156 SBC samples were collected retrospectively and before any BC-related therapy and surgery at University Hospital of Heidelberg during the years 2011-2014 (46 ± 7.3 years old). Blood samples from 151 unrelated cancer free women (no auto-immune diseases and no pregnancy) collected during the years 2011-2014 at the same center of Heidelberg were selected as controls for the Validation III (45 ± 14.5 years old). The same blood processing protocol and DNA isolation protocol were applied to the cases and controls of the Validation III.
Leucocytes
Peripheral blood samples from 36 sporadic BC patients and 36 healthy female controls were randomly selected from the Validation III. Leucocytes were isolated freshly from peripheral blood using red blood cell lysis buffer as described previously (22) within 2 h after blood collection. The leucocytes pellets were snap frozen in liquid nitrogen and kept at −80°C before use. DNA and RNA were isolated from leucocytes using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Cases and controls were processed in parallel.
Blood cell fractionations from leucocytes
Leucocytes were freshly obtained from seven sporadic BC patients and 14 female healthy controls at University Hospital of Heidelberg. These samples were independent from samples in the three validation studies. The isolation of B cells, T cells and 'B/T-lymphocytes-depleted leucocytes' from these samples were described in our previous study (22) . DNA was isolated from different blood cell types using AllPrep DNA/RNA/Protein Mini Kit from Qiagen. All the cases and controls were processed in parallel.
Tissues
For most of the BC patients in Validation III, their tumor tissues are also available for analysis. For this study, tissue samples from 14 benign breast tissues and 34 primary BC tumors (nonmetastasis, randomly selected from Validation III) were obtained at the University Hospital of Heidelberg during surgery. None of these patients were treated by adjuvant therapy before surgery. The tissues were snap frozen in liquid nitrogen after obtained and kept at −80°C before use. DNA and RNA were isolated from tissues using AllPrep DNA/RNA/Protein Mini Kit from Qiagen.
Abbreviations
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breast cancer FBC familial BC ROC receiver operating characteristic Malignant and non-neoplastic tissue were always processed in parallel.
MALDI-TOF mass spectrometry
Agena MALDI-TOF (matrix-assisted laser desorption ionization time-of-flight) mass spectrometry described by Breitling et al (25) . was used in all the candidate approaches for the analyses of S100P methylation in a quantitative manner. The sequence of the investigated region is shown in Supplementary Figure 1 , available at Carcinogenesis Online. Forward primer: aggaagagagG-GAAGGTGGGTTTGAATTTAGTATT; Reverse primer: cagtaatacgactcactatagggagaaggctCTATCCCTCTTACCTCTAAACCCCT.
Uppercase letters indicate the sequence specific primer regions, and non-specific tags are shown in lower case letters. There are no SNPs located in the primer regions, and none of the covered CpGs in the three amplicons are overlapped with known SNPs. For each batch of MassARRAY analysis, equal numbers of cases and controls randomly selected from the cohort were analysed. The samples from BC cases and controls were treated and analysed in parallel in all the processes.
Quantitative real-time PCR
100 ng of total RNA from each sample was reverse transcribed into cDNA using TaqMan® Reverse Transcription Reagents (Applied Biosystems). Relative expression of S100P for each sample was calculated by quantitative real-time PCR according to ΔΔCt method (26) via normalization to the housekeeping gene HPRT1 (hypoxanthine-guanine phosphoribosyltransferase1) using LightCycler 480 in combination with TaqMan gene expression assays (Applied Biosystems).
Statistical analyses
Statistical analyses for the Illumina 27K Array data were described in our previous study (22) . The cell-type proportions were adjusted for the Illumina 27K Array by fitting data linear mixed effects models (27) . The statistical analyses of MassARRAY and gene expression data were conducted by SPSS Statistics 17.0. The correlations between DNA methylation and the disease status were analysed by binary logistic regression adjusted for possible co-founding effects of age and different measurement batches by including additional co-variables into the logistic regression models. The comparisons between two or multiple groups were analysed by non-parametric tests. Receiver operating characteristic (ROC) curve analysis adjusted for co-founding effects of age and different measurement batches was performed to assess the discriminatory power of altered methylation levels. All statistical tests were two-sided, and P values less than 0.05 were considered as statistically significant.
Results
Discovery of BC-associated S100P hypomethylation in blood by Illumina 27K methylation array
We have performed an epigenome-wide screening using Human Methylation27 BeadChip (Illumina) in 72 FBC cases and 24 controls as described in a previous study (22) . CpG site cg22266967 in the S100 calcium binding protein P gene (S100P) presented the most absolute methylation difference between FBC cases and controls (methylation intensity difference = 12.92 %, FDR adjusted P-value = 2.51 × 10 -8
) among the CpG sites with epigenome-wide significance. It has been shown that the distinct blood cell populations have unique DNA methylation signatures, thus the possible disease-related cell heterogeneity in blood may act as a potential confounder when investigating DNA methylation differences between cases and controls (28) . Adjusted for the cell proportions according to the algorithm introduced by Housman et al (27) , cg22266967 still showed significant difference between FBC cases and controls (P = 1.70 × 10 -4 ).
Validation of BC-associated S100P hypomethylation in blood by three independent case-control studies from multicenters
To validate the BC-associated differential S100P methylation in peripheral blood DNA, an amplicon harboring the cg22266967 site and flanking five CpG sites was designed for the analyses by Agena MALDI-TOF mass spectrometry. This amplicon covers the translation region of exon 1 of S100P gene and part of the first intron ( Figure 1A ). S100P_CpG_2 represented cg22266967 and showed the methylation level in combination with S100P_ CpG_3 using MassARRAY (mentioned as S100P_CpG_2.3). Three independent case-control studies from multicenters were performed for the purpose of validation: Validation I with 235 FBC cases and 206 controls; Validation II with 189 SBC cases and 189 controls; Validation III with 156 SBC cases and 151 controls (see Materials and method). In all the three validation studies, except S100P_CpG_4, all the other five CpG sites of S100P showed significantly lower methylation levels in BC cases than in control group with cancer free women (ORs per −1% methylation range from 1.03 to 1.11 depending on the CpG sites, and P < 0.0006 for all CpG sites in all three studies, Figure 1B- note, CpG sites showed similar ORs per −1% methylation and the same rank from the highest odds ratio to the lowest odds ratio in the three independent studies (Supplementary Table 1 , available at Carcinogenesis Online), indicated that the correlation between S100P hypomethylation and BC was independent from family history and independent from different sample processing in multicenters. The correlation between the methylation levels of CpG sites in S100P were also analysed except S100P_ CpG_4, all the other five CpG sites of S100P were significantly and strongly correlated with each other (Spearman rho > 0.45, and P < 2.00 × 10 -20 for all).
S100P methylation and the clinical characteristics of BC
The relationship between blood-based S100P methylation and the clinical characteristics of BC was investigated. Since no clinical data were available for the FBC patients, the analyses were only performed in the SBC patients from the Validation II and Validation III whose clinical data were available. S100P methylation showed weak correlation with the menopausal status of the BC patients in Validation II, but showed no association with all other analysed clinical features in both validation studies (Supplementary Tables  2 and Table 3 , available at Carcinogenesis Online).
Inverse correlation between the methylation and expression of S100P in peripheral blood leucocytes
To understand the correlation between methylation and the expression of S100P gene in blood cells, DNA and RNA were isolated from peripheral blood leucocytes of 36 SBC patients and 36 healthy controls, which were randomly selected from Validation III. Except S100P_CpG_4, significantly lower methylation was observed in five CpG sites of S100P in the leucocytes DNA from BC cases compared to that from controls even with such limited sample size (P < 0.01, Figure 2A) . Although the methylation level difference of S100P CpG sites was only 5-10% between the BC patients and controls, the median of relative expression levels of S100P in the leucocytes of these BC cases was 2.6-fold higher than in the controls (S100P relative expression, median and inter-quartile range (IQR) of cases: 3.47 (1.23-20.77), median and IQR of controls: 1.31 (0.72-2.07), P = 0.001, Figure 2B ). Except S100P_CpG_4, The methylation levels of the five CpG sites were significantly and inversely correlated with the expression levels of S100P with Spearman rhos < -0.43 (P < 1.2 × 10 -4 for all). The methylation level of S100P_CpG_8 showed the most strong correlation with the expression of S100P with Spearman rho of -0.54 (P = 9.55 × 10 -7 , Figure 2C ).
Replication of S100P methylation differences in T cells
Next, we attempted to replicate the methylation differences in freshly sorted leucocytes fragments. B cells, T cells and the B/T-lymphocytes-depleted leucocytes (mainly granulocytes, monocytes and NK cells) were sorted from seven SBC cases and 14 healthy controls. All the subjects were collected and processed in parallel (see materials and method). The methylation levels of all the S100P CpG sites were higher in the B cells and T cells than in the B/T-lymphocytes-depleted leucocytes (Figure 3) . For the T cell fraction and the B/T-lymphocytes-depleted leucocytes fraction, all the six CpG loci in S100P showed lower methylation in SBC cases than in the controls. Of these, S100P_CpG_2.3 and S100P_CpG_8 had significant difference between cases and controls even with very small sample size (P < 0.05, Figure 3) . In contrast, the SBC cases had a slightly higher S100P methylation in the B cells than the controls but results were not significant (Figure 3 ).
S100P methylation in BC tumor
S100P methylation and expression were further analysed in the tissue samples from 14 benign breast tissues and 34 primary BC tumors (non-metastatic), which were obtained at the University Hospital of Heidelberg during surgery (BC patients were recruited in the Validation III). None of these patients were treated by adjuvant therapy before surgery. All the measurable CpG sites in S100P showed lower methylation in the primary BC tumors than the benign tissues. Of these, S100P_CpG_2.3, S100P_CpG_7 and S100P_CpG_9 had significant difference between cancer and benign tissue even with small sample size (P < 0.005, Figure 4A ). This 15%-20% methylation level difference of the S100P CpG sites between the SBC tumors and benign tissues resulted in 10-folds S100 expression difference (S100P relative expression, median , Figure 4B ). The methylation levels of all the six CpG sites were significantly and inversely correlated with the expression levels of S100P with a Spearman rho < -0.44 (P < 1.1 × 10 -4 for all). In tissue, S100P_CpG_9 showed the most strong correlation with the expression (Spearman rho = −0.77 (P = 2.56 × 10 −10 , Figure 4C ). The correlation of S100P methylation between tissue and blood was further analysed in paired samples from these 48 subjects. The methylation levels of these S100P CpG sites had no significant correlation between tissue and blood (Spearman rho from −0.24 to 0.11, P > 0.18 for all, Supplementary Table 4, available at Carcinogenesis Online).
S100P methylation as a marker for the detection of BC
To estimate the potential clinical utility of S100P methylation as a marker for the predictive of BC presence, ROC curve analyses were performed using all analysed S100P CpG sites adjusted for age and different batches by logistic regression. The S100P methylation showed better discriminatory power for differentiating BC cases from healthy controls in Validation I than Validation II and III (area under curve (AUC) = 0.81, 0.68 and 0.70, respectively, Table 2 ). When stratified by age, S100P methylation showed robust discriminatory power for BC in the women younger than 50 years (AUC > 0.84 for all three validation studies, Table 2 ). To note, since the samples from the three studies were from different centers and collected via different blood processing manner, the ROC analyses were performed independently in each validation round, but not with training-testing statistical model.
Discussion
In our study, we has discovered and validated the correlation association between S100P methylation in blood cells and BC with more than 1100 subjects using MassARRAY. Differences in methylation profiles might be influenced by the proportions of the leucocytes subpopulations, if cell distribution itself differs by disease status. According to our Illumina 27K data, BC patients had a 5% higher granulocyte proportion than unaffected controls, whereas the proportion of T cells, natural killer cells, B cells and monocytes were similar between BC patients and controls (22) . However, the change of leucocytes subpopulation proportion was not the only reason for the observed differential S100P methylation in peripheral blood. In this study, we reported BC-associated altered S100P methylation in T cells, and in other leucocyte subpopulations except B cells. Alternatively, the methylation pattern might be affected by lifestyle, environment factors (29, 30) , and other BC-related factors, which were unfortunately not available in our study and warrant further investigation in the future. S100P is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100P has been shown to mediate tumor growth, metastasis and invasion through the binding of Ca2+ ions (31) . S100P could activate MAPK and NF-κB pathways and promote tumor cell proliferation via upregulation of cell cycle factor cyclin D1 and CDK (32) . As an oncogene, demethylation of the S100P promoter was significantly correlated with high mRNA/protein expression of S100P in colorectal cancer tissues (33) . Moreover, the association between high S100P expression in tumor and a more aggressive tumor phenotype has been reported in the metastasis development of lung cancer (34) and the shorter survival of triple negative BC patients (35) . The over-expression of S100P in the pancreatic juice is also considered as an indication of early stage carcinogenesis of pancreatic cancer (36) . In agreement with these observations, our results also confirmed the oncogenic character of S100P in tissue by observing lower S100P methylation levels and higher S100P expression in primary BC tumors compared to benign breast tissues. In our study, the other possibility for the origin of the observed altered S100P methylation in blood is the circulating tumor DNA. However, the S100P methylation patterns in tissue had no correlation with that in blood of the same patients. In addition, the proportion of tumor DNA in blood would be minuscule compared with blood cell DNA (ratio about 1:1000) (37) , and thus, would be very unlikely to change the overall blood methylation values. Therefore, the observed BC-associated differential S100P methylation in blood is not originated from the circulating tumor DNA. Inversely correlated with expression, the decreased S100P methylation in blood cells might be biologically meaningful. However, the function of S100P in hematopoietic systems is still unknown. Recent genome-wide association studies also did not report any significant association between S100P genomic variation and BC risk. Future studies for the mechanisms of S100P in blood cells or immune cells may provide hints for its involvement in initiation and progression of cancer. Nevertheless, we could not exclude the possibility that the altered S100P methylation might just be subsequent marker of carcinogenesis without being directly involve in the process.
In this study, we reported a significant correlation between blood-based S100P hypomethylation and the presence of BC. The similar methylation levels between BC with differential clinical characteristics (including receptor status, stage, grading and menopause status) further suggested that decreased S100P methylation might be applied for the detection of BC, especially for detection of BC in women under 50 years. Although the mechanism of BC-associated S100P methylation in blood cells is still unknown, the application of S100P methylation as a sensitive bio-marker should be highlighted, especially as the origination of this marker from leucocyte subpopulations has been addressed.
Recent years, there are many reports about the leucocytes methylation and BC, especially for the LINE1. The inconsistent results and lack of reproducibility make LINE difficult for the clinical usage (38) . In addition, LINE1 is repetitive elements and thus the copies of the LINE1 element changes not only in patients, but may also among healthy individuals (39) . The methylation of LINE1 could also be influenced by variant deletion in the LINE1 region (39) . Therefore, it is difficult to establish a threshold for 'positivity' LINE 1 methylation. Moreover, the reported ORs of LINE for cancer risk in quartile analysis (lowest quartile vs. highest quartile) are mostly less than 2.0 (19, 38, 40) , which is too low to be a efficient marker. In contrast, S100P has only two copies in every normal cells of every individuals. There is so far no report about the structural changes (eg. deletion, amplification) in the altered methylation region of S100P. The high ORs of S100P for BC in quartile analysis (odds ratio lowest quartile vs. highest quartile range from 5 to 20 in three validation studies, data not shown) suggests the high potential that S100P to be a translational marker. Nevertheless, S100P alone may not be sufficient enough for the detection of BC. A marker panel with several DNA methylation markers or even in combination with other types of blood marker may be considered to improve the diagnostic efficiency.
Nevertheless, due to the limitation of a retrospective study, our discovery could only suggest the blood-based DNA methylation markers as early diagnostic marker for BC. To determine if these biomarkers constitute early diagnosis markers, multicenter clinical studies with prospective design in population based cohort is will be a mandatory of future studies.
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Supplementary data are available at Carcinogenesis Online.
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